Navigation Links
Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
Date:6/11/2008

$136,231,087 $137,644,883

CYBERONICS, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited except where indicated)

For the Thirteen For the Fifty-Two

Weeks Ended Weeks Ended

April 25, April 27, April 25, April 27,

2008 2007 2008 2007

(Audited)

Net sales $33,891,644 $31,431,839 $121,229,742 $130,968,437

Cost of sales 5,893,833 5,725,732 21,092,374 18,258,374

Gross Profit 27,997,811 25,706,107 100,137,368 112,710,063

Operating Expenses:

Selling, general

and

administrative 19,763,932 29,173,816 85,944,866 134,144,315

Research and

development 5,210,171 6,732,491 22,421,199 28,092,243

Total Operating

Expenses 24,974,103 35,906,307 108,366,065 162,236,558

Operating

Earnings/

(Loss) 3,023,708 (10,200,200) (8,228,697) (49,526,495)

Interest income 698,663 1,033,156 3,844,508 4,649,394

Interest expense (1,119,284) (1,552,842) (5,818,272) (5,913,119)

Other expense, net (5,887) (50,917) (397,141) (311,112)

Earnings (loss)

before income

taxes 2,597,200 (10,770,803) (10,599,602) (51,101,332)

Income tax expense

(benefit) (306,154) (3,086) (264,837) 78,775

Net Earnings

(Loss) $2,903,354 $(10,767,717) $(10,334,765) $(51,180,107)

Basic Earnings

(Loss) per share $0.11 $(0.42) $(0.39) $(2.01)

Diluted Earnin
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
2. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
3. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
4. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
5. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
6. Rosetta Genomics Reports First Quarter 2008 Financial Results
7. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
8. Advance Nanotech Reports First Quarter 2008 Financial Results
9. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
10. Senetek PLC Reports First Quarter 2008 Financial Results
11. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... SAN DIEGO , Dec. 15, 2014 /PRNewswire/ ... a three-dimensional biology company focused on delivering breakthrough ... by the industry and collaborators of its exVive3D ... was made widely available in full commercial release ... in the field, resulting in several awards for ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
(Date:12/13/2014)... Clarassance, a privately held clinical-stage biotechnology company ... Therabron Therapeutics , Inc. The new name is derived ... structure in the lungs similar to branches on a ... protein therapeutics for the treatment of respiratory diseases. ... name to mark the company's escalation into the clinical ...
(Date:12/13/2014)... The “Global Synthetic Biology Market ... threats, opportunities, and challenges. , The global synthetic ... namely, Thermo Fisher Scientific, Inc. (U.S.), DuPont (U.S.), ... accounted for approximately ~65% of the total synthetic ... for This Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3
... , , STAMFORD, Conn. ... and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) today announced ... Intermezzo ((R)) (zolpidem tartrate sublingual tablet) in the United States. If ... ((R)) has the potential to be the first prescription sleep aid ...
... ... Terrosa Technologies, a provider of Cloud and SaaS ... world wide sales, marketing and distribution responsibilities with Integrated Clinical ... collaboration Clinical Trial Management System (CTMS) tool for the pharmaceutical ...
... time bomb, a deadly mechanism that can be used against ... Universiteit Brussel (VUB) were able to determine the structure and ... for finding ways to set the clock on this internal ... new class of antibiotics. The research was accepted for ...
Cached Biology Technology:Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 2Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 3Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 4Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 5Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 6Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 7Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 3Bacteria pack their own demise 2Bacteria pack their own demise 3
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... native flora is in sourcing genetically diverse seed not ... seed. "A common belief is that local native ... projects," says Dr Linda Broadhurst from CSIRO, Australia,s national ... that local seed is adapted to local conditions and ...
... A wild fungus has been found to produce a ... microscopic fungus, known as Gliocladium roseum (NRRL ... rainforest. Gary Strobel of Montana State University ... and that the particular diesel components produced can be ...
... discovered a metabolic deficiency in pancreatic cancer cells that ... deadliest of all cancers. Published in the October ... study results indicate that pancreatic cancer cells cannot produce ... in cell division, immune function and hormone regulation. By ...
Cached Biology News:Obscure fungus produces diesel fuel components 2UC Davis researchers discover Achilles' heel in pancreatic cancer 2UC Davis researchers discover Achilles' heel in pancreatic cancer 3
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Request Info...
Amyloid stain....
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Biology Products: